JP2024504366A5 - - Google Patents
Info
- Publication number
- JP2024504366A5 JP2024504366A5 JP2023544294A JP2023544294A JP2024504366A5 JP 2024504366 A5 JP2024504366 A5 JP 2024504366A5 JP 2023544294 A JP2023544294 A JP 2023544294A JP 2023544294 A JP2023544294 A JP 2023544294A JP 2024504366 A5 JP2024504366 A5 JP 2024504366A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- syndrome
- items
- disease
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140488P | 2021-01-22 | 2021-01-22 | |
| US63/140,488 | 2021-01-22 | ||
| PCT/US2022/012739 WO2022159373A1 (en) | 2021-01-22 | 2022-01-18 | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504366A JP2024504366A (ja) | 2024-01-31 |
| JP2024504366A5 true JP2024504366A5 (cg-RX-API-DMAC7.html) | 2025-01-27 |
Family
ID=80820704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544294A Pending JP2024504366A (ja) | 2021-01-22 | 2022-01-18 | 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240092881A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4281472A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024504366A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230134533A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022210283A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173016A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304593A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022159373A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| CN116194478A (zh) | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
| TW202426048A (zh) * | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
| CA3266977A1 (en) * | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP5878270B2 (ja) | 2012-12-19 | 2016-03-08 | プロメラス， エルエルシー | 高純度ノルボルネンアルカノールおよびその誘導体の製造方法 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| ES2965486T3 (es) * | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12240893B2 (en) * | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| JP7511566B2 (ja) * | 2019-01-25 | 2024-07-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
| MX2021009789A (es) * | 2019-02-14 | 2021-11-17 | Alexion Pharma Inc | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada. |
| JP2023501377A (ja) * | 2019-11-08 | 2023-01-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 高濃度抗ｃ５抗体配合物 |
| CN116194478A (zh) * | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
-
2022
- 2022-01-18 CA CA3173016A patent/CA3173016A1/en active Pending
- 2022-01-18 AU AU2022210283A patent/AU2022210283A1/en active Pending
- 2022-01-18 WO PCT/US2022/012739 patent/WO2022159373A1/en not_active Ceased
- 2022-01-18 US US18/272,906 patent/US20240092881A1/en active Pending
- 2022-01-18 KR KR1020237027849A patent/KR20230134533A/ko active Pending
- 2022-01-18 EP EP22704040.9A patent/EP4281472A1/en not_active Withdrawn
- 2022-01-18 EP EP24158584.3A patent/EP4378479A3/en active Pending
- 2022-01-18 JP JP2023544294A patent/JP2024504366A/ja active Pending
-
2023
- 2023-07-19 IL IL304593A patent/IL304593A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250002567A1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| JP2021167362A (ja) | 補体関連障害を処置するための方法および組成物 | |
| JP6013733B2 (ja) | Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ | |
| US11203628B2 (en) | CD200 mutants and its uses | |
| JP2020528894A5 (cg-RX-API-DMAC7.html) | ||
| ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
| JP2015526064A5 (cg-RX-API-DMAC7.html) | ||
| JP2024518163A5 (cg-RX-API-DMAC7.html) | ||
| JP2021525718A5 (cg-RX-API-DMAC7.html) | ||
| EP3876961A1 (en) | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same | |
| JP2024504366A (ja) | 抗ｃ５抗体を使用して補体媒介血栓性微小血管障害症を治療する方法 | |
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| US20190151414A1 (en) | Anti-complement factor c4/c4b antibodies and uses thereof | |
| US20230040568A1 (en) | Kir3dl3 is an inhibitory receptor of the immune system and uses thereof | |
| WO2025087363A1 (zh) | 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法 | |
| JP2020507569A5 (cg-RX-API-DMAC7.html) | ||
| TW202525323A (zh) | 用ＴＡＣＩ－Ｆｃ融合蛋白治療ＡＮＣＡ相關性血管炎的方法 | |
| Kamble | Orthotopic heart transplant facilitated autologous hematopoietic stem cell transplantation in light-chain amyloidosis | |
| JP2018526346A (ja) | 免疫調節疾患および障害の治療方法および組成物 | |
| CN121001740A (zh) | 一种复方制剂及其应用 | |
| TW202525840A (zh) | 用ＴＡＣＩ－Ｆｃ融合蛋白治療抗體介導性排斥反應的方法 | |
| CN122070144A (zh) | 用于治疗自身免疫病的产品和方法 | |
| CN116490209A (zh) | 联合疗法及其使用方法 | |
| CN115611981A (zh) | 抗pd-1抗体在治疗外周t细胞淋巴瘤中的应用 | |
| Kacani et al. | Detachment of HIV-1 from follicular dendritic cells by blocking the C3D-CR2 interaction |